Kaplan Fox Urges Investors of Smartsheet Inc. (SMAR) with Significant Losses to Seek a Leadership Role Before October 5, 2026

Kaplan Fox & Kilsheimer LLP announced a class action lawsuit against Smartsheet Inc. (NYSE: SMAR) covering sellers of common stock during June 1, 2024 to September 23, 2024. The filing signals potential litigation risk for shareholders who held/sold during the class period, though no financial impacts or allegations details are provided in the release. Expect limited near-term impact unless further specifics emerge.

Analysis

This looks like a classic plaintiff-firm headline with limited standalone economic content. For SMAR, the market mechanism is not direct damages; it is whether the complaint uncovers a disclosure problem severe enough to change the revenue quality narrative and force a lower EV/revenue multiple. Absent an accounting restatement, SEC inquiry, or revised guidance, the first reaction is usually an air pocket that mean-reverts once investors realize the claim is procedural rather than fundamental.

The real risk window is 1-3 months, not today: motion-to-dismiss timing, any D&O reserve disclosure, auditor language, or an 8-K around legal contingency could extend the overhang. The tail case is that this becomes a proxy for prior-quarter demand softness or sales-practice issues; in that scenario the hit is larger than legal expense because it would validate a higher churn/discount-rate regime across mid-cap SaaS.

Competitive spillover is mostly valuation rather than operations. If SMAR de-rates on litigation optics, higher-quality workflow SaaS names with cleaner execution records such as TEAM or MNDY can gain on a relative basis, but there is no obvious supply-chain winner. The contrarian view is that the market often overprices class-action headlines before any damages model is even credible; without hard evidence, this is usually a headline beta event, not an earnings event.

Key Decisions for Investors

• Do not initiate an outright short in SMAR on this headline alone; expected downside is mostly multiple compression, and absent a disclosure issue the move should fade within days. Falsifier: no SEC inquiry, no reserve build, and no guidance change on the next print.
• If SMAR sells off >5% on the tape without new fundamental evidence, consider a tactical long for a 1-4 week mean-reversion trade with a tight stop below the event low; risk/reward is favorable only if the market is pricing litigation as if it were a restatement.
• Relative-value idea: long TEAM or MNDY vs short SMAR over the next 1-3 months if the complaint gains traction, because the market will likely punish the lowest-trust name first. Exit if SMAR reaffirms bookings and cRPO trends on earnings.
• Avoid buying SMAR puts into this headline unless implied volatility remains cheap; the better payoff comes if later filings reveal accounting or disclosure issues. Otherwise option premium likely decays faster than the legal overhang develops.
• Set an alert for any 8-K, 10-Q legal reserve disclosure, or SEC correspondence; that is the first point where this shifts from noise to a fundamentals-driven de-rating.